STOCK TITAN
  1. Home
  2. News
  3. STOK

Stoke Therapeutics Inc - STOK STOCK NEWS

Welcome to our dedicated news page for Stoke Therapeutics (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stoke Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stoke Therapeutics's position in the market.

News
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
Rhea-AI Summary
Stoke Therapeutics (STOK) presents new data on STK-001 at the American Epilepsy Society 2023 Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.47%
Tags
conferences
-
News
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) reported positive data from ongoing studies of STK-001, showing substantial reductions in seizure frequency and improvements in cognition and behavior in patients with Dravet syndrome. The company plans to complete Phase 1/2a studies by year-end and meet with regulators to discuss a Phase 3 study design in 1H 2024. As of September 30, 2023, Stoke had $214.7 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.53%
Tags
earnings
-
News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Rhea-AI Summary
Stoke Therapeutics grants stock option to new employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.8%
Tags
none
News
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Stoke Therapeutics to participate in panel presentation at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.53%
Tags
conferences
-
News
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
Rhea-AI Summary
Stoke Therapeutics appoints Ian Smith to its Board of Directors, bringing significant experience in the development of medicines for rare genetic diseases. Smith's expertise and track record in the biotech industry will be valuable as Stoke advances STK-001 for Dravet syndrome. This represents a unique opportunity to develop disease-modifying medicines for challenging diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
management
-
News
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
Rhea-AI Summary
Stoke Therapeutics presents data on STK-001 for Dravet syndrome at IEC 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
clinical trial
News
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
Rhea-AI Summary
Stoke Therapeutics, Inc. reported positive data on STK-001 for Dravet syndrome, showing reductions in seizures and improvements in cognition and behavior. The company plans to share an update on Phase 3 planning in 1H 2024. Stoke also received authorization for a Phase 1 study of STK-002 for Autosomal Dominant Optic Atrophy. As of June 30, 2023, the company had $231.4 million in cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
earnings
-
News
Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Summary
Stoke Therapeutics, Inc. (Nasdaq: STOK) to Present at Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
-
News
Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
Rhea-AI Summary
Stoke Therapeutics announces positive safety and efficacy data for STK-001 in Dravet syndrome patients aged 2 to 18. The data shows reductions in convulsive seizure frequency and improvements in cognition and behavior, supporting the potential for disease modification. Additional data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.11%
Tags
clinical trial
News
Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome
Rhea-AI Summary
Stoke Therapeutics to present new data from ongoing studies in Dravet syndrome
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.73%
Tags
conferences clinical trial
Stock STOK logo
Stoke Therapeutics Inc

Nasdaq:STOK

STOK Rankings

#2761 Ranked by Market Cap
#5271 Ranked by Stock Gains
N/A Ranked by Dividends

STOK Stock Data

662.24M
35.46M
4.64%
88.08%
10.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About STOK

stoke is developing antisense oligonucleotide medicines that target rna splicing to increase gene expression for the treatment of severe genetic diseases.